The pharmaceutical landscape is evolving rapidly, and staying ahead of the curve means keeping a close pulse on the industry’s biggest gatherings. In a recent episode of the DES Pharma Podcast, our hosts reflect on the recently concluded DCAT Week and look ahead to the American Society of Gene & Cell Therapy (ASGCT) annual meeting.
From the rise of complex biologics to the new, rigorous realities of biotech funding, here is a breakdown of the key insights and trends currently shaping our industry.
DCAT Week Recap: The Shift to Complex Biologics
For decades, DCAT (Drug, Chemical & Associated Technologies Association) has been a cornerstone event for pharmaceutical networking. However, the nature of the conference, and the industry it represents, has undergone a noticeable transformation, even for pharma consultants.
Then vs. Now
Isaac Jagenothan, a veteran attendee, recalled the days when DCAT was primarily centralized at the Waldorf Astoria, with a heavy focus almost exclusively on small molecule APIs. Fast forward to today, and the environment has expanded significantly. Not only is the event now spread across several hotels in Midtown Manhattan, but the scientific focus has also broadened. Traditional CDMOs that once specialized solely in small molecules are aggressively building out their bio-sectors.
The Rise of ADCs and Bispecifics
Madawa highlighted a clear market trajectory observed during their CDMO and CRO meetings: a pivot toward more complex biologics. While classical biologic products like monoclonal antibodies remain strong, the industry’s focus and investment are shifting heavily toward:
-
Antibody-Drug Conjugates (ADCs)
-
Bispecific antibodies
-
Peptides
The Power of Spontaneous Networking
For first-time attendee Matthew Pontrelli, the value of DCAT was clear: unparalleled access to business leaders and decision-makers. Beyond the highly anticipated, pre-scheduled hotel suite meetings, the true magic often happens in the lobbies and lounges. The shared, patient-focused culture of the event makes it incredibly easy to strike up a conversation over coffee, share best practices, and build valuable partnerships.
Looking Ahead: What to Expect at ASGCT
With DCAT in the rearview mirror, the DES Pharma team is gearing up for ASGCT in Boston from May 11th through the 15th.
As the largest nonprofit medical and scientific organization dedicated to advanced therapies, ASGCT serves the entire cell, gene, and nucleic acid therapy ecosystem. The vibe here contrasts sharply with DCAT:
-
Centralized Location: Held in a single convention center rather than decentralized hotel suites.
-
Science-Heavy Focus: A deep dive into the latest data on new viral vector production systems, delivery vehicles, and DNA systems.
-
Innovator Showcase: The premier stage for innovator companies to present their work, attract investors, and secure clinical collaborations.
The New Biotech Funding Reality
One of the most pressing topics for companies heading into ASGCT is the current investment climate. The days of securing funding based purely on early proof of concept are largely over. Investors are now operating with a much higher threshold for risk.
To secure funding today, pre-clinical and mid-stage biotech companies must present:
-
A proven track record of engagement with regulatory agencies.
-
A clear, rigorous clinical development strategy.
-
A sharply defined eye on commercial manufacturability and cost.
How DES Pharma Bridges the Gap
Rising technical demands from investors don’t have to be a roadblock. DES Pharma provides comprehensive support to help cell and gene therapy programs clear these new hurdles:
-
Grant Writing: Leveraging in-house expertise to secure non-dilutive funding.
-
Due Diligence Packages: Building robust, investor-ready data packages that cover all technical bases.
-
Regulatory Strategy: Guiding early-stage companies through critical agency interactions, such as INTERACT meetings, to gain investor confidence.
-
Technical Operations: Providing CMC support and batch release oversight to prevent serious adverse events that could derail a clinical program.
Alex has 20+ years of experience in the CMC space, specializing in CDMO/CRO management, analytical development, technology transfer, quality and regulatory compliance for various drug modalities across multiple product stages.
Reach out to Alex on LinkedIn.
